Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... antibody platform, used Sangamo's ZFNs to knock out the gene encoding rat immunoglobulin M (IgM), an important gene for rat antibody production. Inactivation of ... rats that exclusively express human antibodies encoded by transgenic human immunoglobulin genes. "Creating a knockout rat was the biggest challenge OMT faced," ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... that LymphoStat-B also promoted progressive normalization of autoantibody, immunoglobulin and complement levels over 2.5 years of therapy in SLE patients (Stohl et ... presentation reporting the progressive normalization of autoantibody, immunoglobulin and complement levels over 2.5 years of treatment with LymphoStat-B, click ...

Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease

... Liquid [Immune Globulin Intravenous (Human)] (IGIV), an intravenous immunoglobulin preparation, for the treatment of patients with mild to moderate ... a broad spectrum of immunoglobulins (antibodies), and is indicated as an immunoglobulin replacement therapy in patients with primary immunodeficiency. GAMMAGARD ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

... injection, is a novel-engineered fusion protein, consisting of a dipeptidyl peptidase-IV (DDP-IV) protected GLP-1 analog linked to a fragment of immunoglobulin G4 that is believed to increase the duration of its pharmacological effect. Based on this study presented at this year's ADA meeting, LY2189265 is ...

Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy

... doses. About IgA Nephropathy IgA nephropathy is the most common primary cause of kidney disease and occurs as a result of the deposition of immunoglobulin A in the kidney. The injured kidney tissues secrete a variety of inflammatory mediators including CCL2. CCL2 in the tissue causes CCR2-expressing ...

Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma

... as compared to placebo. Secondary endpoints include pulmonary function, time to exacerbation, daily peak expiratory flow (PEF) and symptom scores, immunoglobulin E (IgE) levels, and fractional concentration of expired nitric oxide (FeNO). "Regulatory clearance and initiation of AeroTrial are significant ...

Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis

... or CLL markers, using a method called flow cytometry, and by using molecular techniques to confirm the presence of certain rearranged genes, known as immunoglobulin heavy variable (IGHV) group genes, found in CLL. In 41 patients, MBL was confirmed by both methods. The study, titled "B-Cell Clones as Early ...

ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

... first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragment frameworks. ESBATech's unique, scientific approach ...

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

... first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragment frameworks. ESBATech's unique, scientific approach ...

ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications

... first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... S/D and GAMMAGARD LIQUID, marketed as KIOVIG in the European Union, contain a broad spectrum of immunoglobulins (antibodies) and are indicated as an immunoglobulin replacement therapy that boosts the immune system in patients with primary immunodeficiency disorders. The precise mechanisms of GAMMAGARD S/D and ...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

... called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white ...

Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer

... chronic inflammatory disorder of the airways resulting in airway obstruction. In some patients, allergens, such as pollen, trigger the production of immunoglobulin E (IgE) antibodies, which then bind to mast cells and transmit intracellular signals causing the allergic response. In May 2006, Pfizer selected R343 ...

Haemacure Announces Preliminary Findings of its Plasma Discard Analysis

... including albumin, plasminogen, immunoglobulin and A1PI. These findings take on a strategic ... market was estimated at US$2.4 billion in 2006. immunoglobulin is the biggest selling protein in North America, ... billion in 2006 in the United States alone. immunoglobulin is used to treat immunological, neurological and ...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

... antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other ...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

... in the ImClone pipeline that target other critical cancer pathways. Like ERBITUX, the monoclonal antibodies in the ImClone pipeline are all type 1 immunoglobulin G (IgG1) antibodies. In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute ...

Global Rabies Treatment May be Possible with NanoViricides Drugs

... ligand class were tested in both direct intracerebral treatment as well as intraperitoneal treatment modalities. Human anti-Rabies immunoglobulin (RIG), a commercial standard rabies treatment, was used as positive control. A 30% survival rate with two of the nanoviricides and 20% survival ...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

... received 10 mg/kg, exhibited stable disease for over six months. Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, ...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

... antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other ...

Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO

... with advanced solid tumors. Like its marketed product ERBITUX(R) (cetuximab), the monoclonal antibodies in the ImClone pipeline are all type 1 immunoglobulin G (IgG1) antibodies. In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute ...

Genetic Analysis Systems Enter the Clinical Mainstream

... use in this country. For example, PerkinElmers Cerebrospinal Fluid Kit provides a sensitive and rapid method of separating and detecting oligoclonal immunoglobulin bands in unconcentrated cerebrospinal fluid using isoelectric focusing. The presence or absence of these bands is important as supporting evidence ...